as of 07-17-2026 2:15pm EST
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 10.3M | IPO Year: | 2022 |
| Target Price: | $13.00 | AVG Volume (30 days): | 71.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | -1.04 | EPS Growth: | 23.94 |
| 52 Week Low/High: | $2.29 - $14.64 | Next Earning Date: | 05-08-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -2.22 | Index: | N/A |
| Free Cash Flow: | -12606770.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chairman and CEO
Avg Cost/Share
$3.03
Shares
7,400
Total Value
$22,422.00
Owned After
98,589
SEC Form 4
Chairman, CEO and Interim CFO
Avg Cost/Share
$3.20
Shares
2,277
Total Value
$7,286.40
Owned After
98,589
SEC Form 4
Chairman, CEO and Interim CFO
Avg Cost/Share
$3.55
Shares
9,167
Total Value
$32,542.85
Owned After
98,589
SEC Form 4
Chairman, CEO and Interim CFO
Avg Cost/Share
$3.16
Shares
513
Total Value
$1,621.08
Owned After
98,589
SEC Form 4
Chairman, CEO and Interim CFO
Avg Cost/Share
$3.18
Shares
3,613
Total Value
$11,489.34
Owned After
98,589
SEC Form 4
Chairman, CEO and Interim CFO
Avg Cost/Share
$3.58
Shares
3,666
Total Value
$13,124.28
Owned After
98,589
SEC Form 4
Chairman, CEO and Interim CFO
Avg Cost/Share
$3.94
Shares
12,996
Total Value
$51,204.24
Owned After
98,589
SEC Form 4
Chairman, CEO and Interim CFO
Avg Cost/Share
$4.12
Shares
1,462
Total Value
$6,023.44
Owned After
98,589
SEC Form 4
CEO and Chairman
Avg Cost/Share
$4.46
Shares
349
Total Value
$1,556.54
Owned After
98,589
SEC Form 4
CEO and Chairman
Avg Cost/Share
$5.01
Shares
303
Total Value
$1,518.03
Owned After
98,589
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Pham Quang X | CVKD | Chairman and CEO | Jun 29, 2026 | Sell | $3.03 | 7,400 | $22,422.00 | 98,589 | |
| Pham Quang X | CVKD | Chairman, CEO and Interim CFO | Jun 23, 2026 | Sell | $3.20 | 2,277 | $7,286.40 | 98,589 | |
| Pham Quang X | CVKD | Chairman, CEO and Interim CFO | Jun 22, 2026 | Sell | $3.55 | 9,167 | $32,542.85 | 98,589 | |
| Pham Quang X | CVKD | Chairman, CEO and Interim CFO | Jun 17, 2026 | Sell | $3.16 | 513 | $1,621.08 | 98,589 | |
| Pham Quang X | CVKD | Chairman, CEO and Interim CFO | Jun 16, 2026 | Sell | $3.18 | 3,613 | $11,489.34 | 98,589 | |
| Pham Quang X | CVKD | Chairman, CEO and Interim CFO | Jun 15, 2026 | Sell | $3.58 | 3,666 | $13,124.28 | 98,589 | |
| Pham Quang X | CVKD | Chairman, CEO and Interim CFO | Jun 12, 2026 | Sell | $3.94 | 12,996 | $51,204.24 | 98,589 | |
| Pham Quang X | CVKD | Chairman, CEO and Interim CFO | Jun 11, 2026 | Sell | $4.12 | 1,462 | $6,023.44 | 98,589 | |
| Pham Quang X | CVKD | CEO and Chairman | Jun 2, 2026 | Sell | $4.46 | 349 | $1,556.54 | 98,589 | |
| Pham Quang X | CVKD | CEO and Chairman | May 29, 2026 | Sell | $5.01 | 303 | $1,518.03 | 98,589 |
SEC 8-K filings with transcript text
May 7, 2026 · 100% conf.
1D
-2.41%
$5.88
5D
-5.33%
$5.70
20D
-8.97%
$5.48
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784333246.425805bf
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Mar 31, 2026
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.e618d017.1784333248.42582c2c
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Nov 10, 2025 · 100% conf.
1D
-4.25%
$11.26
Act: +5.02%
5D
-6.96%
$10.94
Act: -0.51%
20D
-12.94%
$10.24
Act: -15.22%
false 0001937993
0001937993
2025-11-10 2025-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 10, 2025
Cadrenal Therapeutics, Inc.
(Exact name of registrant as specified in charter)
Delaware
001-41596
88-0860746
(State or other jurisdiction
of incorporation)
(Commission File Number)
Employer
Identification No.)
822 A1A North, Suite 306
Ponte Vedra, Florida 32082
(Address of principal executive offices and zip code)
(904) 300-0701
(Registrant’s telephone number including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbols
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 10, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are furnished with this Current Report on Form 8-K:
Exhibit
Number
Exhibit Description
99.1
Press Release, issued by Cadrenal Therapeutics, Inc. on November 10, 2025
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)
1
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 10, 2025
By: /s/ Quang X. Pham
Name: Quang X. Pham
Title: Chairman and Chief Executive Officer
2
See how CVKD stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CVKD Cadrenal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.